CRL

357.27

3.45% 11.90

시장 영업 전: 359.98 2.71 +0.76%

Charles River Laboratories International Inc (CRL)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

전일 마감가:

$345.37

열려 있는:

$347.59

하루 거래량:

1.18M

Relative Volume:

0.94

시가총액:

$17.06B

수익:

$4.03B

순이익/손실:

$-182.84M

주가수익비율:

-95.01

EPS:

-3.7603

순현금흐름:

$391.29M

1주 성능:

+13.26%

1개월 성능:

+22.00%

6개월 성능:

+108.65%

1년 성능:

+82.95%

1일 변동 폭

$0.00

1주일 범위

$313.83

$357.77

52주 변동 폭

$146.19

$357.77

Charles River Laboratories International Inc Stock (CRL) Company Profile

명칭

Charles River Laboratories International Inc

부문

Healthcare (1053)

산업

Diagnostics & Research (44)

전화

781-222-6000

주소

251 BALLARDVALE ST, WILMINGTON, MA

직원

19,700

트위터

@criverlabs

다음 수익 날짜

2026-11-04

최신 SEC 제출 서류

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, NTRA, A, IQV

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CRL Charles River Laboratories International Inc	357.27	17.06B	4.03B	-182.84M	391.29M	-3.7603
TMO Thermo Fisher Scientific Inc	684.89	253.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.97	163.77B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	404.90	58.36B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	175.96	49.61B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	273.60	45.03B	16.63B	1.39B	2.12B	8.0674

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-09-30	재개	UBS	Buy
2026-08-06	업그레이드	JP Morgan	Neutral → Overweight
2026-07-20	다운그레이드	CLSA	Outperform → Hold
2026-06-17	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2026-05-29	업그레이드	CLSA	Hold → Outperform
2026-04-14	개시	RBC Capital Mkts	Outperform
2025-12-15	업그레이드	BofA Securities	Neutral → Buy
2025-11-17	업그레이드	Argus	Hold → Buy
2025-11-06	업그레이드	Robert W. Baird	Neutral → Outperform
2025-10-06	업그레이드	William Blair	Mkt Perform → Outperform
2025-10-02	업그레이드	Barclays	Equal Weight → Overweight
2025-09-09	업그레이드	Jefferies	Hold → Buy
2025-07-09	업그레이드	Citigroup	Neutral → Buy
2025-05-23	업그레이드	Redburn Atlantic	Neutral → Buy
2025-05-14	업그레이드	TD Cowen	Hold → Buy
2025-05-08	업그레이드	Evercore ISI	In-line → Outperform
2025-03-21	다운그레이드	Goldman	Buy → Neutral
2025-03-04	업그레이드	Citigroup	Sell → Neutral
2025-03-03	업그레이드	Redburn Atlantic	Sell → Neutral
2025-01-22	다운그레이드	William Blair	Outperform → Mkt Perform
2025-01-17	다운그레이드	UBS	Buy → Neutral
2024-11-18	다운그레이드	CLSA	Hold → Underperform
2024-11-07	업그레이드	CLSA	Underperform → Hold
2024-10-23	개시	CLSA	Underperform
2024-10-14	개시	Redburn Atlantic	Sell
2024-10-07	다운그레이드	Evercore ISI	Outperform → In-line
2024-10-02	다운그레이드	BofA Securities	Buy → Neutral
2024-10-01	다운그레이드	Citigroup	Neutral → Sell
2024-08-08	다운그레이드	JP Morgan	Overweight → Neutral
2024-08-08	다운그레이드	Robert W. Baird	Outperform → Neutral
2024-06-28	다운그레이드	Argus	Buy → Hold
2024-06-07	개시	Mizuho	Neutral
2024-06-06	개시	Goldman	Buy
2024-02-15	다운그레이드	Guggenheim	Buy → Neutral
2023-09-13	개시	TD Cowen	Market Perform
2023-07-10	다운그레이드	Citigroup	Buy → Neutral
2023-02-23	업그레이드	Guggenheim	Neutral → Buy
2023-01-12	다운그레이드	Jefferies	Buy → Hold
2022-09-30	업그레이드	Jefferies	Hold → Buy
2022-08-25	개시	Credit Suisse	Outperform
2022-08-04	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	개시	Guggenheim	Neutral
2022-04-25	다운그레이드	Jefferies	Buy → Hold
2022-04-07	개시	Stephens	Overweight
2022-02-17	재확인	BofA Securities	Buy
2022-02-17	업그레이드	Citigroup	Neutral → Buy
2022-02-17	재확인	Deutsche Bank	Buy
2022-02-17	재확인	Morgan Stanley	Overweight
2022-02-17	재확인	UBS	Buy
2021-08-05	재개	Credit Suisse	Neutral
2020-12-16	다운그레이드	Citigroup	Buy → Neutral
2020-09-10	업그레이드	Jefferies	Hold → Buy
2020-07-01	업그레이드	BofA Securities	Neutral → Buy
2020-05-13	업그레이드	UBS	Neutral → Buy
2020-04-21	다운그레이드	Jefferies	Buy → Hold
2020-03-27	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	개시	Deutsche Bank	Buy
2020-02-18	업그레이드	Wolfe Research	Peer Perform → Outperform
2020-01-10	업그레이드	Goldman	Neutral → Buy
2020-01-08	개시	Wells Fargo	Overweight
2020-01-07	개시	Citigroup	Buy
2019-10-18	다운그레이드	BofA/Merrill	Buy → Neutral
2019-06-10	개시	SVB Leerink	Outperform
2019-04-30	재개	Evercore ISI	Outperform
2018-12-14	개시	Deutsche Bank	Buy
2018-10-09	개시	UBS	Neutral
2018-08-23	업그레이드	Raymond James	Mkt Perform → Outperform
2018-07-17	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	업그레이드	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	업그레이드	SunTrust	Hold → Buy

모두보기

Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스

Oct 26, 2026

Charles River Laboratories’ Q3 2026 Earnings: What to Expect - Yahoo Finance

Oct 26, 2026

Oct 25, 2026

Charles River Laboratories International (CRL) Has Fresh Attention, But What Is Behind It? - Simply Wall Street

Oct 25, 2026

Oct 23, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 23, 2026

Charles River Laboratories International, Inc. Estimates – NYSE:CRL - TradingView

Oct 23, 2026

Oct 22, 2026

Charles River Laboratories (CRL) Partners with FDA and Labcorp t - GuruFocus

Oct 22, 2026

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 22, 2026

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Finviz

Oct 22, 2026

Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5 - Yahoo Finance

Oct 22, 2026

Oct 21, 2026

$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today - Benzinga

Oct 21, 2026

Charles River (CRL) Stock Charges Higher On Bullish Targets And AI Hype - Timothy Sykes

Oct 21, 2026

Charles River Laboratories International Jumps 7.3% in Broad Rally - AlphaStreet

Oct 21, 2026

Charles River Labs Stock Jumps As Street Hikes Targets - StocksToTrade

Oct 21, 2026

Charles River Laboratories stock hits 52-week high at 333.31 USD - Investing.com

Oct 21, 2026

Charles River Laboratories stock hits 52-week high at 333.31 USD By Investing.com - Investing.com South Africa

Oct 21, 2026

Oct 20, 2026

Is Charles River Laboratories International Inc (CRL) Overvalued After 5.1% Rally? GF Value Says Overvalued - GuruFocus

Oct 20, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 20, 2026

Dilution adjustment of Charles River Laboratories International, Inc. – XETR:RV6 - TradingView

Oct 20, 2026

Morgan Stanley lifts target for Charles River Laboratories stock to USD 340.00 - ad-hoc-news.de

Oct 20, 2026

AI-Driven Drug Discovery Boosts Charles River Laboratories (CRL) Prospects - GuruFocus

Oct 20, 2026

Citrini Bets on Life Sciences Stocks After Claude AI Drug Study - Bloomberg.com

Oct 20, 2026

Oct 17, 2026

Charles River Laboratories International (CRL) Earnings Beat Puts Fair Value Back In Focus - Simply Wall Street

Oct 17, 2026